Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina
- 30 September 2001
- journal article
- Published by Elsevier in Mechanisms of Ageing and Development
- Vol. 122 (16) , 2057-2062
- https://doi.org/10.1016/s0047-6374(01)00314-1
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Guidelines for the Appropriate Use of Cholinesterase Inhibitors in Patients with Alzheimer??s DiseaseCNS Drugs, 1999
- Donepezil Improves Cognition and Global Function in Alzheimer DiseaseA 15-Week, Double-blind, Placebo-Controlled StudyArchives of internal medicine (1960), 1998
- A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's diseaseNeurology, 1998
- RivastigmineDrugs & Aging, 1998
- Butyrylcholinesterase in the life cycle of amyloid plaquesAnnals of Neurology, 1997
- Disaggregation of Alzheimer β-amyloid by site-directed mAbProceedings of the National Academy of Sciences, 1997
- A Monoclonal Antibody against Acetylcholinesterase Inhibits the Formation of Amyloid Fibrils Induced by the EnzymeBiochemical and Biophysical Research Communications, 1997
- Acetylcholinesterase Accelerates Assembly of Amyloid-β-Peptides into Alzheimer's Fibrils: Possible Role of the Peripheral Site of the EnzymePublished by Elsevier ,1996
- Chapter 53: Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's diseasePublished by Elsevier ,1993
- A new and rapid colorimetric determination of acetylcholinesterase activityBiochemical Pharmacology, 1961